A Long-term, Open-label Follow-up Study Of Tofacitinib (Cp-690,550) For Treatment Of Rheumatoid Arthritis
Latest Information Update: 30 Mar 2022
At a glance
- Drugs Tofacitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Registrational
- Acronyms ORAL-Sequel
- Sponsors Pfizer
- 28 Mar 2022 Results of post hoc analysis, assessing effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis, published in the Clinical Rheumatology
- 09 Nov 2021 Results of post hoc analyses from RCT data: Cohort C, (NCT00814307, NCT02187055); C2, (NCT01039688); and C3, (NCT00413699, NCT00661661) assessing the patient characteristics, efficacy, and treatment patterns for tofacitinib monotherapy in patient with rheumatoid arthritis using RCT data and available RWD, presented at the ACR Convergence 2021.
- 05 Jun 2021 Results (n=2265) of post-hoc analysis from three trials (NCT00847613; NCT00853385, NCT00856544, NCT00661661 and NCT00413699) assessing the impact of sex on efficacy, safety and persistence in tofacitinib rheumatoid arthritis presented at the 22nd Annual Congress of the European League Against Rheumatism